SCHEMBL2274153

SCHEMBL2274153

O[Si](OF)(OF)Oc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.38
TSHR P16473 1/20 0.38
CA5A P35218 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
CA4 P22748 1/20 0.35
NR1H2 P55055 1/20 0.34
BAX Q07812 1/20 0.34
ALDH1A1 P00352 1/20 0.33
RECQL P46063 1/20 0.33
SRC P12931 1/20 0.33
ALOX15 P16050 1/20 0.32
KCNA3 P22001 1/20 0.32
MLYCD O95822 1/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
KCNH2 Q12809 1/20 0.30
LMNA P02545 1/20 0.30
KDM4E B2RXH2 1/20 0.30
GLA P06280 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1217901 0.85 LTA4H (0.45) LTA4HTSHRCA5ACA5BCA4
Fluoride SCHEMBL27845931 0.82 LTA4H (0.43) LTA4HTSHRCA5ACA5BCA4
SCHEMBL896125 0.79 LTA4H (0.45) LTA4HTSHRCA5ACA5BCA4
SCHEMBL4813685 0.77 LTA4H (0.43) LTA4HTSHRCA5ACA5BCA4
SCHEMBL28193743 0.76 CA4 (0.46) LTA4HTSHRCA5ACA5BCA4
SCHEMBL27845667 0.75 LTA4H (0.41) LTA4HTSHRCA5ACA5BCA4
SCHEMBL230789 0.74 LTA4H (0.45) LTA4HTSHRCA5ACA5BCA4
SCHEMBL28053677 0.73 CA4 (0.42) LTA4HTSHRCA5ACA5BCA4
SCHEMBL4807486 0.72 LTA4H (0.43) LTA4HTSHRCA5ACA5BCA4
SCHEMBL4809947 0.72 LTA4H (0.43) LTA4HTSHRCA5ACA5BCA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3180324-A1 HYPERVALENT IODINE CF2CF2X REAGENTS AND THEIR USE ETH Zürich (CH) 2017-06-21 EP claimed
WO-2016019475-A1 HYPERVALENT IODINE CF2CF2X REAGENTS AND THEIR USE ETH ZURICH (CH) 2016-02-11 WO claimed
US-8791100-B2 Aryl benzylamine compounds NOVARTIS AG (CH) 2014-07-29 US disclosed
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS UGT2B7, NAT1, CYP2B6 LTA4H 1337/4885TSHR 1964/4885CA5A 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.